

Jonathan S Zager

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5691455/publications.pdf>

Version: 2024-02-01

265
papers

10,193
citations

41258

49
h-index

42291

92
g-index

268
all docs

268
docs citations

268
times ranked

10043
citing authors

#	ARTICLE	IF	CITATIONS
1	In-transit metastatic cutaneous melanoma: current management and future directions. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 201-211.	1.7	6
2	Sentinel lymph node biopsy in melanoma: beyond histologic factors. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 29-38.	1.7	11
3	Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival. <i>Journal of Surgical Oncology</i> , 2022, 125, 229-238.	0.8	1
4	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 791-801.	0.7	18
5	External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1637-1644.	0.7	5
6	The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 95-104.	1.9	3
7	ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1647.	0.7	0
8	Is There a Relationship Between TILs and Regression in Melanoma?. <i>Annals of Surgical Oncology</i> , 2022, 29, 2854-2866.	0.7	5
9	ASO Author Reflections: Is There a Relationship Between TIL and Regression in Melanoma?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
10	Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?. <i>Cancer</i> , 2022, 128, 1418-1428.	2.0	4
11	Future perspectives: Novel Frontiers in Cancer Metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 255.	1.7	0
12	Editorial: Novel Frontiers in Cancer Metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 1-1.	1.7	2
13	Introduction: Novel Frontiers in Cancer Metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 3-5.	1.7	3
14	Efficacy of Neoadjuvant Intratumoral Dargaxin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM). <i>Annals of Surgical Oncology</i> , 2022, 29, 3377-3378.	0.7	4
15	Dedication to late Dale Han, MD. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 257-257.	1.7	0
16	An update on local and systemic therapies for nonmelanoma skin cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 479-489.	1.1	2
17	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	3.2	36
18	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
19	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
20	Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. <i>Annals of Surgical Oncology</i> , 2021, 28, 1007-1016.	0.7	15
21	Surgeon decision-making for management of positive sentinel lymph nodes in the post-Multicenter Selective Lymphadenectomy Trial II era: A survey study. <i>Journal of Surgical Oncology</i> , 2021, 123, 646-653.	0.8	12
22	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.2	14
23	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
24	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. <i>Annals of Surgery</i> , 2021, 273, 814-820.	2.1	16
25	Molecular Aspects of the Isolated Limb Infusion Procedure. <i>Biomedicines</i> , 2021, 9, 163.	1.4	3
26	Developments in therapy for brain metastases in melanoma patients. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1443-1453.	0.9	1
27	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-II). <i>Cancer</i> , 2021, 127, 2251-2261.	2.0	37
28	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	0.7	8
29	Regression is significantly associated with outcomes for patients with melanoma. <i>Surgery</i> , 2021, 170, 1487-1494.	1.0	7
30	The Surgeons' Role When Systemic Therapies Fail in Metastatic Melanoma: The Salvage Metastasectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 5801-5802.	0.7	1
31	Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 6978-6985.	0.7	13
32	ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 678-679.	0.7	2
33	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 19-29.	0.4	3
34	ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy. <i>Annals of Surgical Oncology</i> , 2021, 29, 802.	0.7	0
35	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021, 43, 539-541.	0.3	2
36	Clinical Insignificance of Percutaneous Hepatic Perfusion-Associated Troponin Elevation. <i>Journal of the American College of Surgeons</i> , 2021, 233, S245.	0.2	0

#	ARTICLE	IF	CITATIONS
37	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. <i>Annals of Surgical Oncology</i> , 2021, 29, 804.	0.7	3
38	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110535.	0.7	7
39	Local and regional therapy for primary and locally recurrent melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 246-260.	0.3	0
40	Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 196-202.	0.7	6
41	Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. <i>Pathology and Oncology Research</i> , 2020, 26, 239-244.	0.9	7
42	ASO Author Reflections: Robotic Pelvic Lymph Node Dissection for Metastatic Melanoma—A Minimally Invasive Approach to a Difficult Problem. <i>Annals of Surgical Oncology</i> , 2020, 27, 203-204.	0.7	0
43	Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 86-95.	1.5	11
44	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 35-42.	0.7	4
45	Management of Locoregionally Advanced Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 109-125.	0.5	5
46	An evaluation of talimogene laherparepvec for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 9-14.	1.4	8
47	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	0.9	11
48	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. <i>World Journal of Surgery</i> , 2020, 44, 1283-1293.	0.8	8
49	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146.	0.5	8
50	Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?. <i>Surgery</i> , 2020, 168, 518-526.	1.0	9
51	Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3234-3235.	0.8	6
52	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
53	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	0.7	8
54	ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5119-5120.	0.7	1

#	ARTICLE	IF	CITATIONS
55	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). <i>Melanoma Management</i> , 2020, 7, MMT41.	0.1	3
56	The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5259-5266.	0.7	5
57	ASO Author Reflection: Isolated Limb Infusion for Locally Advanced Melanoma in the Extremely Old Patient is Safe and Effective. <i>Annals of Surgical Oncology</i> , 2020, 27, 1430-1431.	0.7	2
58	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429.	0.7	10
59	Isolated limb infusion: Institutional protocol and implementation. <i>Journal of Surgical Oncology</i> , 2020, 122, 99-105.	0.8	7
60	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
61	Infusion Technique. , 2020, , 357-366.		1
62	Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. <i>Cancer Control</i> , 2020, 27, 107327482098301.	0.7	7
63	Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice. , 2020, , 379-394.		0
64	Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants. , 2020, , 439-450.		0
65	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
66	Management of Locally and Regionally Recurrent Melanoma. , 2019, , 515-534.		0
67	Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). <i>Melanoma Management</i> , 2019, 6, MMT19.	0.1	21
68	Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. <i>EBioMedicine</i> , 2019, 47, 89-97.	2.7	39
69	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
70	Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. <i>Future Oncology</i> , 2019, 15, 3665-3674.	1.1	14
71	Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. <i>Head and Neck</i> , 2019, 41, 871-879.	0.9	13
72	Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. <i>Journal of the American College of Surgeons</i> , 2019, 228, 644-649.	0.2	65

#	ARTICLE	IF	CITATIONS
73	Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. <i>Melanoma Management</i> , 2019, 6, MMT17.	0.1	0
74	ASO Author Reflections: International Experience of Isolated Limb Infusion for Melanoma Shows Durable Response. <i>Annals of Surgical Oncology</i> , 2019, 26, 2495-2496.	0.7	0
75	Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. <i>Annals of Surgical Oncology</i> , 2019, 26, 2254-2262.	0.7	26
76	Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. <i>Journal of Surgical Oncology</i> , 2019, 119, 1053-1059.	0.8	12
77	Long-term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	0.7	35
78	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
79	Management of intussusception in patients with melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 897-902.	0.8	5
80	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.1	6
81	The emergence of neoadjuvant therapy in advanced melanoma. <i>Melanoma Management</i> , 2019, 6, MMT27.	0.1	12
82	Locoregional melanoma: identifying optimal care in a rapidly changing landscape. <i>Melanoma Management</i> , 2019, 6, MMT22.	0.1	0
83	Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma. <i>Melanoma Management</i> , 2019, 6, MMT26.	0.1	5
84	Microsatellitosis in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 33-41.	0.7	11
85	Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. <i>Annals of Surgical Oncology</i> , 2019, 26, 379-385.	0.7	36
86	Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00mm): A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 433-440.	0.6	15
87	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	2.0	29
88	Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 9559-9559.	0.8	12
89	Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND). <i>Journal of Clinical Oncology</i> , 2019, 37, 9590-9590.	0.8	1
90	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0

#	ARTICLE	IF	CITATIONS
91	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1
92	Intralesional therapy as a treatment for locoregionally metastatic melanoma. Expert Review of Anticancer Therapy, 2018, 18, 399-408.	1.1	18
93	Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Research, 2018, 28, 134-142.	0.6	20
94	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology, 2018, 117, 1170-1178.	0.8	65
95	Stratifying SLN incidence in intermediate thickness melanoma patients. American Journal of Surgery, 2018, 215, 699-706.	0.9	26
96	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clinical and Experimental Metastasis, 2018, 35, 487-493.	1.7	26
97	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. Cancer, 2018, 124, 2254-2255.	2.0	0
98	Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 469-473.	1.5	9
99	Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 747-753.	0.6	27
100	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer, 2018, 124, 297-305.	2.0	76
101	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Annals of Surgical Oncology, 2018, 25, 356-377.	0.7	130
102	Considerations for Nonmelanoma Skin Cancer: Clinical Presentation. , 2018, , 75-87.		0
103	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 399-413.	0.8	190
104	Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?. Expert Opinion on Biological Therapy, 2018, 18, 1199-1207.	1.4	16
105	Editorial. Clinical and Experimental Metastasis, 2018, 35, 359-360.	1.7	2
106	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. OncoTargets and Therapy, 2018, Volume 11, 9081-9089.	1.0	41
107	Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Annals of Surgical Oncology, 2018, 25, 3960-3965.	0.7	67
108	ASO Author Reflections: Resection Margins in Merkel Cell Carcinoma: Is a 1cm Margin Wide Enough?. Annals of Surgical Oncology, 2018, 25, 901-901.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Management of Locally and Regionally Recurrent Melanoma. , 2018, , 1-20.		0
110	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Management, 2018, 5, MMT02.	0.1	4
111	Future perspectives: cancer metastases. Clinical and Experimental Metastasis, 2018, 35, 559-561.	1.7	2
112	Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Annals of Surgical Oncology, 2018, 25, 3334-3340.	0.7	38
113	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Frontiers in Oncology, 2018, 8, 44.	1.3	67
114	Regional therapies for locoregionally advanced and unresectable melanoma. Clinical and Experimental Metastasis, 2018, 35, 495-502.	1.7	12
115	Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer, 2018, 18, 130.	1.1	117
116	Current standards of surgical management in primary melanoma. Italian Journal of Dermatology and Venereology, 2018, 153, 56-67.	0.1	3
117	Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. Journal of the American College of Surgeons, 2017, 224, 635-642.	0.2	21
118	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 2017, 75, 47-55.	1.3	145
119	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2017, 24, 2089-2094.	0.7	22
120	Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. American Journal of Surgery, 2017, 213, 921-925.	0.9	4
121	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	13.9	1,087
122	Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. Annals of Plastic Surgery, 2017, 78, 663-667.	0.5	10
123	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 473-482.	2.3	25
124	Metastasectomy for Abdominal Visceral Oligometastatic Melanoma. JAMA Surgery, 2017, 152, 678.	2.2	4
125	Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. Annals of Surgical Oncology, 2017, 24, 3842-3849.	0.7	32
126	Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 3803-3810.	0.7	45

#	ARTICLE	IF	CITATIONS
127	Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy—This Time It's Personal. <i>JAMA Dermatology</i> , 2017, 153, 857.	2.0	8
128	Pre-SN Ultrasound-FNAC for Lymph Node Metastases in Melanoma Patients: A Reply. <i>Annals of Surgical Oncology</i> , 2017, 24, 663-664.	0.7	0
129	Chemosaturation with Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases. <i>Cancer Control</i> , 2017, 24, 96-101.	0.7	10
130	Comparison of Single-Photon Emission Computed Tomography—Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. <i>Annals of Surgical Oncology</i> , 2017, 24, 355-361.	0.7	26
131	Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. <i>International Journal of Surgery Oncology</i> , 2017, 2, e43-e43.	0.2	5
132	Improving clinical outcomes with pembrolizumab in patients with advanced melanoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 2-2.	0.4	4
133	Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. <i>American Surgeon</i> , 2016, 82, 1109-1116.	0.4	15
134	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma. <i>Melanoma Research</i> , 2016, 26, 83-87.	0.6	21
135	The safety of talimogene laherparepvec for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2016, 16, 1-5.	1.0	19
136	Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. <i>Brachytherapy</i> , 2016, 15, 495-503.	0.2	10
137	Intralesional and systemic immunotherapy for metastatic melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1491-1499.	1.4	15
138	Talimogene laherparepvec: overview, combination therapy and current practices. <i>Melanoma Management</i> , 2016, 3, 267-272.	0.1	8
139	Intraperitoneal Rosai—Dorfman disease associated with clear cell sarcoma: first case report. <i>Pathology</i> , 2016, 48, 742-744.	0.3	7
140	Art, Science, and Personalized Cancer Care through Regional Therapeutics. <i>Cancer Control</i> , 2016, 23, 3-4.	0.7	0
141	Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 3572-3578.	0.7	77
142	Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. <i>Journal of the American College of Surgeons</i> , 2016, 222, 702-709.	0.2	12
143	Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2330-2335.	0.7	49
144	Is a Wider Margin (2 cm vs. 1 cm) for a 1.0–2.0 mm Melanoma Necessary?. <i>Annals of Surgical Oncology</i> , 2016, 23, 2336-2342.	0.7	15

#	ARTICLE	IF	CITATIONS
145	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.	0.7	236
146	Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2016, 113, 98-102.	0.8	11
147	Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1309-1319.	0.7	117
148	Developments in Intralesional Therapy for Metastatic Melanoma. <i>Cancer Control</i> , 2016, 23, 12-20.	0.7	36
149	Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. <i>World Journal of Clinical Oncology</i> , 2016, 7, 174.	0.9	20
150	Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. <i>American Surgeon</i> , 2016, 82, 1109-1116.	0.4	7
151	Both tumor depth and diameter are predictive of sentinel lymph node status and survival in <scp>M</scp>erkel cell carcinoma. <i>Cancer</i> , 2015, 121, 3252-3260.	2.0	62
152	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2780-2788.	0.8	1,988
153	BRAF and MEK inhibition in melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 559-570.	1.0	67
154	Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 482-488.	0.7	36
155	Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. <i>Current Problems in Cancer</i> , 2015, 39, 248-257.	1.0	10
156	Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. <i>Cancer</i> , 2015, 121, 1628-1636.	2.0	43
157	A Multicenter Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2015, 22, 287-294.	0.7	24
158	Sentinel Lymph Node Mapping in Melanoma in the Twenty-first Century. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 249-260.	0.6	23
159	Genetic Testing in the Multidisciplinary Management of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 779-793.	0.6	3
160	Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma. <i>PLoS ONE</i> , 2015, 10, e0119716.	1.1	27
161	Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. <i>PLoS ONE</i> , 2015, 10, e0140362.	1.1	76
162	Intralesional therapy for metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2629-2639.	0.9	18

#	ARTICLE	IF	CITATIONS
163	MSLT-1â€”putting sentinel lymph node biopsy into context. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 246-248.	12.5	6
164	Radiotherapy influences local control in patients with desmoplastic melanoma. <i>Cancer</i> , 2014, 120, 1369-1378.	2.0	58
165	Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1355-1364.	1.5	17
166	Analysis of Tumor Mitotic Rate in Thin Metastatic Melanomas Compared With Thin Melanomas Without Metastasis Using Both the Hematoxylin and Eosin and Anti-phosphohistone 3 IHC Stain. <i>American Journal of Dermatopathology</i> , 2014, 36, 64-67.	0.3	10
167	A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology. <i>Cancer Prevention Research</i> , 2014, 7, 496-504.	0.7	22
168	Resection of Residual Disease after Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 650-655.	0.7	23
169	Recent developments in the medical and surgical treatment of melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 171-185.	157.7	56
170	Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience. <i>Journal of Surgical Oncology</i> , 2014, 109, 434-439.	0.8	43
171	Isolated hepatic perfusion for metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 383-388.	0.8	9
172	Locoregional Therapies in Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1003-1015.	0.5	27
173	Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. <i>Cancer</i> , 2014, 120, 781-789.	2.0	79
174	Occult Primary, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 969-974.	2.3	27
175	Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 425-431.	2.3	7
176	Interclavicular Stabilization With the Synthes Sternal Fixation System After Radical Manubriectomy: Report of 3 Cases. <i>Chest</i> , 2014, 145, 35A.	0.4	0
177	Cutaneous Angiosarcoma: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 3391-3397.	0.7	66
178	Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 893-899.	1.5	64
179	Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. <i>Cancer Epidemiology</i> , 2013, 37, 434-439.	0.8	59
180	Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 680-688.	0.7	138

#	ARTICLE	IF	CITATIONS
181	Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy?. <i>Annals of Surgical Oncology</i> , 2013, 20, 2345-2351.	0.7	46
182	Isolated Limb Infusion in a Series of Over 100 Infusions: A Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 1121-1127.	0.7	41
183	A Collision of Diseases: Chronic Lymphocytic Leukemia Discovered During Lymph Node Biopsy for Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 1360-1364.	0.7	17
184	^{99m} Tc-tilmanocept for lymphoscintigraphy. <i>Imaging in Medicine</i> , 2013, 5, 119-125.	0.0	4
185	Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4387-4393.	0.8	204
186	Pediatric melanoma: Analysis of an international registry. <i>Cancer</i> , 2013, 119, 4012-4019.	2.0	71
187	A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. <i>Hpb</i> , 2013, 15, 655-660.	0.1	10
188	The use of isolated limb infusion in limb threatening extremity sarcomas. <i>International Journal of Hyperthermia</i> , 2013, 29, 1-7.	1.1	14
189	Recent Advances in the Treatment of Melanoma. <i>Cancer Control</i> , 2013, 20, 244-245.	0.7	2
190	Identifying Risk Factors Using a Skin Cancer Screening Program. <i>Cancer Control</i> , 2013, 20, 248-254.	0.7	27
191	Cutaneous Leiomyosarcoma: Treatment and Outcomes with a Standardized Margin of Resection. <i>Cancer Control</i> , 2013, 20, 307-312.	0.7	46
192	Controversies in the Evaluation and Management of Atypical Melanocytic Proliferations in Children, Adolescents, and Young Adults. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 679-686.	2.3	28
193	Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects. <i>American Surgeon</i> , 2013, 79, 476-482.	0.4	20
194	Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. <i>American Surgeon</i> , 2013, 79, 476-82.	0.4	10
195	A Multicenter Prospective Evaluation of the Clinical Utility of F-18 FDG-PET/CT in Patients With AJCC Stage IIIB or IIIC Extremity Melanoma. <i>Annals of Surgery</i> , 2012, 256, 350-356.	2.1	36
196	Differential gene expression in liposarcoma: A biologic basis for clinically aggressive behavior?. <i>Journal of the American College of Surgeons</i> , 2012, 215, S122-S123.	0.2	0
197	Sentinel Node Biopsy is Indicated for Thin Melanomas. <i>Annals of Surgical Oncology</i> , 2012, 19, 3335-3342.	0.7	64
198	Primary Tumor Thickness as a Prognostic Factor in Merkel Cell Carcinoma: The Next Big Thing?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3307-3309.	0.7	2

#	ARTICLE	IF	CITATIONS
199	The Unique Clinical Characteristics of Melanoma Diagnosed in Children. <i>Annals of Surgical Oncology</i> , 2012, 19, 3888-3895.	0.7	66
200	Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 287-299.	0.6	5
201	Progression of cutaneous melanoma: implications for treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 775-796.	1.7	32
202	Chemosaturation with Percutaneous Hepatic Perfusion for Unresectable Isolated Hepatic Metastases from Sarcoma. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1480-1487.	0.9	16
203	A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. <i>Cancer</i> , 2012, 118, 6136-6143.	2.0	14
204	Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 331-336.	0.7	29
205	A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities. <i>Annals of Surgical Oncology</i> , 2012, 19, 1637-1643.	0.7	40
206	Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1100-1106.	0.7	33
207	Merkel Cell Carcinoma of Unknown Primary Origin. <i>Annals of Surgical Oncology</i> , 2012, 19, 2360-2366.	0.7	58
208	The role of radical amputations for extremity tumors: A single institution experience and review of the literature. <i>Journal of Surgical Oncology</i> , 2012, 105, 149-155.	0.8	26
209	Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1383-1394.	1.5	7
210	Strategies for Solutions in Sarcoma Management. <i>Cancer Control</i> , 2011, 18, 148-149.	0.7	0
211	Current Diagnosis and Management of Retroperitoneal Sarcoma. <i>Cancer Control</i> , 2011, 18, 177-187.	0.7	67
212	Occult Primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1358-1395.	2.3	41
213	Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. <i>Archives of Surgery</i> , 2011, 146, 870.	2.3	38
214	Shave Biopsy Is a Safe and Accurate Method for the Initial Evaluation of Melanoma. <i>Journal of the American College of Surgeons</i> , 2011, 212, 454-460.	0.2	74
215	Predictors of outcome in patients with recurrent gastrointestinal stromal tumors. <i>Journal of the American College of Surgeons</i> , 2011, 213, S131-S132.	0.2	1
216	What is the Significance of the In Transit or Interval Sentinel Node in Melanoma?. <i>Annals of Surgical Oncology</i> , 2011, 18, 3232-3234.	0.7	26

#	ARTICLE	IF	CITATIONS
217	Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1210-1215.	0.8	73
218	Prognostication in Merkel cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 665-667.	1.1	12
219	Profound proliferating angiolymphoid hyperplasia with eosinophilia of pregnancy mimicking angiosarcoma. <i>Cutis</i> , 2011, 88, 122-8.	0.4	8
220	Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?. <i>Annals of Surgical Oncology</i> , 2010, 17, 670-673.	0.7	45
221	Dermatofibrosarcoma Protuberans: How Wide Should We Resect?. <i>Annals of Surgical Oncology</i> , 2010, 17, 2112-2118.	0.7	134
222	The Surgical Management of Primary and Metastatic Merkel Cell Carcinoma. <i>Current Problems in Cancer</i> , 2010, 34, 77-96.	1.0	25
223	Surgically Unresectable Regional Melanoma Metastases in a Patient With Renal Failure and Peripheral Vascular Disease: Are There Safe and Potentially Effective Treatments?. <i>Seminars in Oncology</i> , 2010, 37, 303-313.	0.8	0
224	Imaging of Merkel Cell Carcinoma. <i>Current Problems in Cancer</i> , 2010, 34, 65-76.	1.0	21
225	Merkel Cell Carcinoma: Pathologic Findings and Prognostic Factors. <i>Current Problems in Cancer</i> , 2010, 34, 47-64.	1.0	34
226	Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions. <i>Journal of Clinical Oncology</i> , 2010, 28, 481-486.	0.8	62
227	Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma \leq 1 cm Is Not Justified. <i>Journal of Clinical Oncology</i> , 2010, 28, e7-e7.	0.8	80
228	Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1033-1037.	1.5	2
229	Commentary on pharmacotherapy of regional melanoma therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1-3.	0.9	3
230	Imaging of Merkel Cell Carcinoma. <i>Molecular Medicine and Medicinal</i> , 2010, , 159-180.	0.4	0
231	New Prognostic Factors in Merkel Cell Carcinoma. <i>Molecular Medicine and Medicinal</i> , 2010, , 143-158.	0.4	0
232	A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US. <i>Journal of the American College of Surgeons</i> , 2009, 208, 706-715.	0.2	132
233	Surgical Management of Melanoma-In-Situ Using a Staged Marginal and Central Excision Technique. <i>Annals of Surgical Oncology</i> , 2009, 16, 1526-1536.	0.7	88
234	Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis. <i>Annals of Surgical Oncology</i> , 2009, 16, 2570-2578.	0.7	55

#	ARTICLE	IF	CITATIONS
235	Sentinel Lymph Node Biopsy for Melanoma: Indications and Rationale. <i>Cancer Control</i> , 2009, 16, 234-239.	0.7	69
236	Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios â€” Part II. <i>Cancer Control</i> , 2009, 16, 196-197.	0.7	0
237	Limiting the Morbidity of Inguinal Lymphadenectomy for Metastatic Melanoma. <i>Cancer Control</i> , 2009, 16, 240-247.	0.7	51
238	Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects. <i>Annals of Surgical Oncology</i> , 2008, 15, 1733-1740.	0.7	19
239	Proper Margins of Excision in Dermatofibrosarcoma Protuberans: Wide or Narrow?. <i>Annals of Surgical Oncology</i> , 2008, 15, 2614-2616.	0.7	7
240	Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. <i>International Journal of Hyperthermia</i> , 2008, 24, 275-289.	1.1	48
241	Therapy for Unresectable Recurrent and In-Transit Extremity Melanoma. <i>Cancer Control</i> , 2008, 15, 225-232.	0.7	54
242	Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios. <i>Cancer Control</i> , 2008, 15, 192-194.	0.7	1
243	Ten Best Readings Relating to Melanoma. <i>Cancer Control</i> , 2008, 15, 271-271.	0.7	0
244	Treatment Options for Limited or Symptomatic Metastatic Melanoma. <i>Cancer Control</i> , 2008, 15, 239-247.	0.7	32
245	Cytoreductive Surgery for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 683-693.	0.6	6
246	Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 1870-1877.	0.7	83
247	Multidisciplinary management of special melanoma situations: Oligometastatic disease and bulky nodal sites. <i>Current Oncology Reports</i> , 2007, 9, 417-427.	1.8	13
248	Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 483-90.	0.3	12
249	The Role of Ultrasound in the Surgical Management of Patients Diagnosed with Ductal Carcinoma in Situ of the Breast. <i>Breast Journal</i> , 2006, 12, 212-215.	0.4	4
250	Lymphatic mapping and sentinel node biopsy: A surgical perspective. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 129-134.	2.5	24
251	Upâ€”regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a β 1 34.5 deleted oncolytic herpes virus (G207). <i>FASEB Journal</i> , 2004, 18, 1001-1003.	0.2	62
252	Intussusception: An Uncommon Cause of Postoperative Small Bowel Obstruction after Gastric Bypass. <i>Obesity Surgery</i> , 2004, 14, 116-119.	1.1	37

#	ARTICLE	IF	CITATIONS
253	Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy. <i>Hepatology</i> , 2004, 39, 1525-1532.	3.6	16
254	Efficacy of Multiagent Herpes Simplex Virus Amplicon-Mediated Immunotherapy as Adjuvant Treatment for Experimental Hepatic Cancer. <i>Annals of Surgery</i> , 2002, 236, 337-343.	2.1	23
255	Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 124, 123-129.	0.4	26
256	Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. <i>Cancer Gene Therapy</i> , 2002, 9, 935-945.	2.2	89
257	Laparoscopic Appendectomy for Crohn's Disease of the Appendix Presenting as Acute Appendicitis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2001, 11, 255-258.	0.5	5
258	Interleukin 12 Secretion Enhances Antitumor Efficacy of Oncolytic Herpes Simplex Viral Therapy for Colorectal Cancer. <i>Annals of Surgery</i> , 2001, 233, 819-826.	2.1	63
259	Three Cases of Small Bowel Intussusception in Relation to a Rare Lesion: Inflammatory Fibrous Polyps. <i>Digestive Surgery</i> , 2001, 18, 142-146.	0.6	13
260	Natural Ceramide Reverses Fas Resistance of Acid Sphingomyelinase ⁺ Hepatocytes. <i>Journal of Biological Chemistry</i> , 2001, 276, 8297-8305.	1.6	114
261	Neoadjuvant Interleukin-12 Immunogene Therapy Protects Against Cancer Recurrence After Liver Resection in an Animal Model. <i>Annals of Surgery</i> , 2000, 231, 762-771.	2.1	28
262	Granular cell tumor—A unique neoplasm of the internal anal sphincter. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 1444-1446.	0.7	18
263	Effects of Preexisting Immunity on the Response to Herpes Simplex-Based Oncolytic Viral Therapy. <i>Human Gene Therapy</i> , 2000, 11, 2465-2472.	1.4	84
264	Jejunal Diverticulosis: A Rare Entity with Multiple Presentations, a Series of Cases. <i>Digestive Surgery</i> , 2000, 17, 643-645.	0.6	51
265	Advances in the management of genitourinary melanomas. <i>AME Medical Journal</i> , 0, 4, 41-41.	0.4	3